Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIPRa CAR T cells
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Peptides
- Administration
- Intravenous
01
Overview
VIPRa CAR T cells are an engineered cellular immunotherapy designed to overcome the immunosuppressive effects of the vasoactive intestinal peptide (VIP) signaling axis in the tumor microenvironment. These CAR T cells are genetically modified to continuously and locally secrete a synthetic short peptide that acts as a VIP receptor antagonist (VIPRa). VIP is a neuropeptide often overproduced by hematologic malignancies that suppresses adaptive immune responses and promotes T-cell exhaustion. By blocking VIP receptors on the CAR T cells themselves and in the surrounding environment, VIPRa CAR T cells exhibit improved metabolic fitness, enhanced mitochondrial activity, reduced exhaustion, and superior in vivo expansion compared to conventional CAR T cells. This approach aims to improve the efficacy of CAR T therapy in blood cancers by neutralizing a key mechanism of immune evasion.
- Other names
- VIP receptor antagonist CAR T cells
02
Targets
VIPR1 (Vasoactive intestinal peptide receptor 1)MAGEA8 (Melanoma-associated antigen 8)VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on VIPRa CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIPRa CAR T cells.